Towards in silico design of epitope-based vaccines

Expert Opinion on Drug Discovery

Volumn 4, Issue 10, 2009, Pages 1047-1060

  Toussaint, Nora C ^a   Kohlbacher, Oliver ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Epitope based vaccines; Immunoinformatics; Immunomics; Vaccine design

Indexed keywords

EPITOPE; EPITOPE BASED VACCINE; HLA DR2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG; VACCINE;

ACCURACY; ANTIGEN PRESENTATION; BINDING AFFINITY; CELLULAR IMMUNITY; DRUG DESIGN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; STANDARD; T LYMPHOCYTE; TECHNIQUE; VALIDATION PROCESS;

EID: 70349404420     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903242283     Document Type: Review

References (140)

1. Moutschen M, Léonard P, Sokal EM, et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 2007;25:4697-4705 (Pubitemid 46766584)
2. Goepfert PA, Tomaras GD, Horton H, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007;25:510-518 (Pubitemid 44856093)
3. Mancini-Bourgine M, Fontaine H, Bréchot C, et al. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 2006;24:4482-4489 (Pubitemid 43792480)
4. Nemunaitis J, Meyers T, Senzer N, et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 2006;13:1185-1191 (Pubitemid 43796154)
5. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007;6:404-414 •• A remarkable review on the potential of epitope-based vaccines and recent developments in the field. (Pubitemid 46696551)
6. Chianese-Bullock KA, Irvin WP, Petroni GR, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 2008;31:420-430
7. Kenter GG, Welters MJP, Valentijn ARPM, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008;14:169-177
8. Slingluff CL, Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007;13:6386-6395
9. Nielsen M, Lundegaard C, Lund O, et al. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 2005;57:33-41 (Pubitemid 40591245)
10. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999;50:201-212 (Pubitemid 30099525)
11. Lund O, Nielsen M, Kesmir C, et al. Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 2004;55:797-810 (Pubitemid 38650985)
12. Van Regenmortel MHV. Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity. Methods 1996;9:465-472
13. Greenbaum JA, Andersen PH, Blythe M, et al. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit 2007;20:75-82 • A workshop report on B-cell epitope prediction tools, including a survey of the available tools and expert recommendations to improve B-cell epitope prediction. (Pubitemid 46761248)
14. Brockman AH, Orlando R, Tarleton RL. A new liquid chromatography/tandem mass spectrometric approach for the identification of class I major histocompatibility complex associated peptides that eliminates the need for bioassays. Rapid Commun Mass Spectrom 1999;13:1024-1030 (Pubitemid 29257204)
15. Schirle M, Keilholz W, Weber B, et al. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 2000;30:2216-2225 (Pubitemid 30655761)
16. Singh-Jasuja H, Emmerich NPN, Rammensee H-G. The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother 2004;53:187-195 (Pubitemid 38328041)
17. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994;153:5586-5592 (Pubitemid 24377694)
18. Lundegaard C, Lund O, Kesmir C, et al. Modeling the adaptive immune system: predictions and simulations. Bioinformatics 2007;23:3265-3275 •• A very thorough review on MHC binding prediction. (Pubitemid 350238877)
19. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning. New York: Springer, 2001
20. Ben-Hur A, Ong CS, Sonnenburg S, et al. Support vector machines and kernels for computational biology. PLoS Comput Biol 2008;4:e1000173
21. Baldi P, Brunak S. Bioinformatics: The Machine Learning Approach. Cambridge, MA: MIT Press, 2001
22. Rammensee H-G, Bachmann J, Emmerich NP, et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-219 •• An important resource for naturally processed MHC ligands. (Pubitemid 30099526)
23. Brusic V, Rudy G, Harrison LC. MHCPEP, a database of MHC-binding peptides: update 1997. Nucleic Acids Res 1998;26:368-371 (Pubitemid 27303192)
24. Bhasin M, Singh H, Raghava GPS. MHCBN: a comprehensive database of MHC binding and non-binding peptides. Bioinformatics 2003;19:665-666 (Pubitemid 36417067)
25. Toseland CP, Clayton DJ, McSparron H, et al. AntiJen: a quantitative immunology database integrating functional, thermodynamic, kinetic, biophysical, and cellular data. Immunome Res 2005;1:4
26. Peters B, Sidney J, Bourne P, et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 2005;3:e91 •• The most comprehensive collection of data related to antibodies and T-cell epitopes. Access to various prediction tools is also provided. (Pubitemid 40605287)
27. Lefranc MP, Giudicelli V, Ginestoux C, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 2009;37:D1006-12 •• The international reference for antibody, T-cell receptor and MHC data.
28. Robinson J, Waller MJ, Stoehr P, et al. IPD-the Immuno Polymorphism Database. Nucleic Acids Res 2005;33:D523-6
29. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res 2000;28:235-242
30. Kaas Q, Ruiz M, Lefranc MP. IMGT/3Dstructure-DB and IMGT/ StructuralQuery, a database and a tool for immunoglobulin, T cell receptor and MHC structural data. Nucleic Acids Res 2004;32:D208-10 (Pubitemid 38081640)
31. Falk K, Rötzschke O, Stevanović S, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-296 (Pubitemid 21896578)
32. Rötzschke O, Falk K, Stevanović S, et al. Exact prediction of a natural T cell epitope. Eur J Immunol 1991;21:2891-2894
33. Meister GE, Roberts CG, Berzofsky JA, et al. Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine 1995;13:581-591
34. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-175 •• The first matrix-based MHC class I binding predictor, which is still widely used today.
35. Stryhn A, Pedersen LO, Romme T, et al. Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. Eur J Immunol 1996;26:1911-1918 (Pubitemid 26283169)
36. Schafer JR, Jesdale BM, George JA, et al. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine 1998;16:1880-1884
37. Reche PA, Glutting J-P, Reinherz EL. Prediction of MHC class I binding peptides using profile motifs. Hum Immunol 2002;63:701-709 (Pubitemid 34983301)
38. Nielsen M, Lundegaard C, Worning P, et al. Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics 2004;20:1388-1397 (Pubitemid 38937025)
39. Bui H-H, Sidney J, Peters B, et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005;57:304-314 (Pubitemid 40905049)
40. Doytchinova IA, Blythe MJ, Flower DR. Additive method for the prediction of protein-peptide binding affinity. Application to the MHC class I molecule HLA-A*0201. J Proteome Res 2002;1:263-272
41. Peters B, Tong W, Sidney J, et al. Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules. Bioinformatics 2003;19:1765-1772 (Pubitemid 37220468)
42. Guan P, Hattotuwagama CK, Doytchinova IA, et al. MHCPred 2.0: an updated quantitative T-cell epitope prediction server. Appl Bioinformatics 2006;5:55-61
43. Guan P, Doytchinova IA, Zygouri C, et al. MHCPred: a server for quantitative prediction of peptide-MHC binding. Nucleic Acids Res 2003;31:3621-3624 (Pubitemid 37442210)
44. Hertz T, Yanover C. PepDist: a new framework for protein-peptide binding prediction based on learning peptide distance functions. BMC Bioinformatics 2006;7(Suppl 1):S3 (Pubitemid 46442949)
45. Sung M-H, Simon R. Genomewide conserved epitope profiles of HIV-1 predicted by biophysical properties of MHC binding peptides. J Comput Biol 2004;11:125-145 (Pubitemid 38429367)
46. Yanover C, Hertz T. Predicting protein-peptide binding affinity by learning peptide-peptide distance functions. in RECOMB. 2005
47. Trost B, Bickis M, Kusalik A. Strength in numbers: achieving greater accuracy in MHC-I binding prediction by combining the results from multiple prediction tools. Immunome Res 2007;3:5 (Pubitemid 46986269)
48. Brusic V, Petrovsky N, Zhang G, et al. Prediction of promiscuous peptides that bind HLA class I molecules. Immunol Cell Biol 2002;80:280-285 (Pubitemid 34639377)
49. Mamitsuka H. Predicting peptides that bind to MHC molecules using supervised learning of hidden Markov models. Proteins 1998;33:460-474 (Pubitemid 28565732)
50. Udaka K, Mamitsuka H, Nakaseko Y, et al. Empirical evaluation of a dynamic experiment design method for prediction of MHC class I-binding peptides. J Immunol 2002;169:5744-5753 (Pubitemid 35291676)
51. Adams HP, Koziol JA. Prediction of binding to MHC class I molecules. J Immunol Methods 1995;185:181-190
52. Brusic V, Rudy G, Harrison LC. Prediction of MHC binding peptides using artificial neural networks. In: RJ Stonier, XH Yu, editors, Complex Systems: Mechanisms of Adaptation, IOS Press: Amsterdam; 1994. p. 253-260
53. Buus S, Lauemøller SL, Worning P, et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 2003;62:378-384
54. Nielsen M, Lundegaard C, Worning P, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003;12:1007-1017 (Pubitemid 36505435)
55. Lundegaard C, Lund O, Nielsen M. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 2008;24:1397-1398
56. Dönnes P, Elofsson A. Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics 2002;3:25 (Pubitemid 38751179)
57. Dönnes P, Kohlbacher O. SVMHC: a server for prediction of MHC-binding peptides. Nucleic Acids Res 2006;34:W194-7 (Pubitemid 44529763)
58. Cui J, Han LY, Lin HH, et al. MHC-BPS: MHC-binder prediction server for identifying peptides of flexible lengths from sequence-derived physicochemical properties. Immunogenetics 2006;58:607-613 (Pubitemid 44100409)
59. Cui J, Han LY, Lin HH, et al. Prediction of MHC-binding peptides of flexible lengths from sequence-derived structural and physicochemical properties. Mol Immunol 2007;44:866-877 (Pubitemid 44415006)
60. Wan J, Liu W, Xu Q, et al. SVRMHC prediction server for MHC-binding peptides. BMC Bioinformatics 2006;7:463 (Pubitemid 44650235)
61. Rognan D, Lauemoller SL, Holm A, et al. Predicting binding affinities of protein ligands from three-dimensional models: application to peptide binding to class I major histocompatibility proteins. J Med Chem 1999;42:4650-4658 (Pubitemid 29530018)
62. Schueler-Furman O, Altuvia Y, Sette A, et al. Structure-based prediction of binding peptides to MHC class I molecules: application to a broad range of MHC alleles. Protein Sci 2000;9:1838-1846 (Pubitemid 30745480)
63. Jojic N, Reyes-Gomez M, Heckerman D, et al. Learning MHC I-peptide binding. Bioinformatics 2006;22:e227-35
64. Zhu S, Udaka K, Sidney J, et al. Improving MHC binding peptide prediction by incorporating binding data of auxiliary MHC molecules. Bioinformatics 2006;22:1648-1655 (Pubitemid 43985299)
65. Heckerman D, Kadie C, Listgarten J. Leveraging information across HLA alleles/supertypes improves epitope prediction. J Comput Biol 2007;14:736-746 (Pubitemid 47221814)
66. Sturniolo T, Bono E, Ding J, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999;17:555-561 •• A key publication on pan-specific MHC (class II) binding prediction. (Pubitemid 29262918)
67. DeLuca DS, Khattab B, Blasczyk R. A modular concept of HLA for comprehensive peptide binding prediction. Immunogenetics 2007;59:25-35 (Pubitemid 46011189)
68. Nielsen M, Lundegaard C, Blicher T, et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS ONE 2007;2:e796
69. Hoof I, Peters B, Sidney J, et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2008;61:1-13 •• State-of-the-art MHC class I binding predictor for all known MHC alleles.
70. Zhang H, Lund O, Nielsen M. The PickPocket method for predicting binding specificities for receptors based on receptor pocket similarities: application to MHC-peptide binding. Bioinformatics 2009;25:1293-1299
71. Jacob L, Vert J-P. Efficient peptide-MHC-I binding prediction for alleles with few known binders. Bioinformatics 2008;24:358-366 (Pubitemid 351189011)
72. Peters B, Bui H-H, Frankild S, et al. A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol 2006;2:e65 • Benchmark of MHC class I binding predictors providing a web-based prediction framework and benchmark data sets. (Pubitemid 43990673)
73. Lin HH, Ray S, Tongchusak S, et al. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol 2008;9:8 (Pubitemid 351583869)
74. Zhang H, Lundegaard C, Nielsen M. Pan-specific MHC class I predictors: a benchmark of HLA class I pan-specific prediction methods. Bioinformatics 2009;25:83-89
75. Larsen MV, Lundegaard C, Lamberth K, et al. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol 2005;35:2295-2303 (Pubitemid 41179750)
76. Eggers M, Boes-Fabian B, Ruppert T, et al. The cleavage preference of the proteasome governs the yield of antigenic peptides. J Exp Med 1995;182:1865-1870
77. Holzhütter HG, Frömmel C, Kloetzel PM. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. J Mol Biol 1999;286:1251-1265 (Pubitemid 29116689)
78. Holzhütter HG, Kloetzel PM. A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates. Biophys J 2000;79:1196-1205
79. Mishto M, Luciani F, Holzhütter H-G, et al. Modeling the in vitro 20S proteasome activity: the effect of PA28-alphabeta and of the sequence and length of polypeptides on the degradation kinetics. J Mol Biol 2008;377:1607-1617
80. Ginodi I, Vider-Shalit T, Tsaban L, et al. Precise score for the prediction of peptides cleaved by the proteasome. Bioinformatics 2008;24:477-483 (Pubitemid 351256290)
81. Kuttler C, Nussbaum AK, Dick TP, et al. An algorithm for the prediction of proteasomal cleavages. J Mol Biol 2000;298:417-429
82. Nussbaum AK, Kuttler C, Hadeler KP, et al. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 2001;53:87-94
83. Keŝmir C, Nussbaum AK, Schild H, et al. Prediction of proteasome cleavage motifs by neural networks. Protein Eng 2002;15:287-296 (Pubitemid 34532767)
84. Dönnes P, Kohlbacher O. Integrated modeling of the major events in the MHC class I antigen processing pathway. Protein Sci 2005;14:2132-2140 (Pubitemid 41132379)
85. Bhasin M, Raghava GPS. Pcleavage: an SVM based method for prediction of constitutive proteasome and immunoproteasome cleavage sites in antigenic sequences. Nucleic Acids Res 2005;33:W202-7 (Pubitemid 44529909)
86. van Endert PM, Riganelli D, Greco G, et al. The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med 1995;182:1883-1895
87. Daniel S, Brusic V, Caillat-Zucman S, et al. Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. J Immunol 1998;161:617-624 (Pubitemid 28323522)
88. Brusic V, van Endert P, Zeleznikow J, et al. A neural network model approach to the study of human TAP transporter. In Silico Biol 1999;1:109-121
89. Zhang GL, Petrovsky N, Kwoh CK, et al. PRED(TAP): a system for prediction of peptide binding to the human transporter associated with antigen processing. Immunome Res 2006;2:3
90. Bhasin M, Raghava GPS. Analysis and prediction of affinity of TAP binding peptides using cascade SVM. Protein Sci 2004;13:596-607 (Pubitemid 38252556)
91. Peters B, Bulik S, Tampe R, et al. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol 2003;171:1741-1749 (Pubitemid 36966457)
92. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001;193:73-88
93. Hakenberg J, Nussbaum AK, Schild H, et al. MAPPP: MHC class I antigenic peptide processing prediction. Appl Bioinformatics 2003;2:155-158
94. Singh H, Raghava GPS. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 2003;19:1009-1014 (Pubitemid 36675822)
95. Reche PA, Glutting J-P, Zhang H, et al. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 2004;56:405-419 (Pubitemid 39359226)
96. Bhasin M, Raghava GPS. A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes. J Biosci 2007;32:31-42 (Pubitemid 46465755)
97. Larsen MV, Lundegaard C, Lamberth K, et al. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 2007;8:424
98. Doytchinova IA, Guan P, Flower DR. EpiJen: a server for multistep T cell epitope prediction. BMC Bioinformatics 2006;7:131
99. Tenzer S, Peters B, Bulik S, et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci 2005;62:1025-1037
100. Bhasin M, Raghava GPS. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine 2004;22:3195-3204
101. Tung C-W, Ho S-Y. POPI: predicting immunogenicity of MHC class I binding peptides by mining informative physicochemical properties. Bioinformatics 2007;23:942-949 • Prediction of T-cell reactivity.
102. Hammer J, Bono E, Gallazzi F, et al. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 1994;180:2353-2358 (Pubitemid 24351618)
103. Marshall KW, Wilson KJ, Liang J, et al. Prediction of peptide affinity to HLA DRB1*0401. J Immunol 1995;154:5927-5933
104. Southwood S, Sidney J, Kondo A, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998;160:3363-3373 (Pubitemid 28164729)
105. Jung G, Fleckenstein B, von der Mülbe F, et al. From combinatorial libraries to MHC ligand motifs, T-cell superagonists and antagonists. Biologicals 2001;29:179-181
106. Brusic V, Rudy G, Honeyman G, et al. Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics 1998;14:121-130 (Pubitemid 28395870)
107. Bhasin M, Raghava GPS. SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence. Bioinformatics 2004;20:421-423 (Pubitemid 38262776)
108. Murugan N, Dai Y. Prediction of MHC class II binding peptides based on an iterative learning model. Immunome Res 2005;1:6
109. Wang P, Sidney J, Dow C, et al. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008;4:e1000048 (Pubitemid 351656722)
110. Mallios RR. Predicting class II MHC/ peptide multi-level binding with an iterative stepwise discriminant analysis meta-algorithm. Bioinformatics 2001;17:942-948
111. Doytchinova IA, Flower DR. Towards the in silico identification of class II restricted T-cell epitopes: a partial least squares iterative self-consistent algorithm for affinity prediction. Bioinformatics 2003;19:2263-2270
112. Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 2007;8:238 (Pubitemid 47225391)
113. Noguchi H, Kato R, Hanai T, et al. Hidden Markov model-based prediction of antigenic peptides that interact with MHC class II molecules. J Biosci Bioeng 2002;94:264-270 (Pubitemid 35192075)
114. Kato R, Noguchi H, Honda H, et al. Hidden Markov model-based approach as the first screening of binding peptides that interact with MHC class II molecules. Enzyme Microbiol Technol 2003;33:472-481 (Pubitemid 37011398)
115. Godkin AJ, Smith KJ, Willis A, et al. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. J Immunol 2001;166:6720-6727 (Pubitemid 32467215)
116. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001;17:1236-1237 (Pubitemid 33735355)
117. Nielsen M, Lundegaard C, Blicher T, et al. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol 2008;4:e1000107
118. Davies MN, Sansom CE, Beazley C, et al. A novel predictive technique for the MHC class II peptide-binding interaction. Mol Med 2003;9:220-225 (Pubitemid 38858176)
119. Zaitlen N, Reyes-Gomez M, Heckerman D, et al. Shift-invariant adaptive double threading: learning MHC II-peptide binding. J Comput Biol 2008;15:927-942
120. Lin HH, Zhang GL, Tongchusak S, et al. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics 2008;9(Suppl 12):S22 (Pubitemid 351583869)
121. Feldhahn M, Thiel P, Schuler MM, et al. EpiToolKit - a web server for computational immunomics. Nucleic Acids Res 2008;36:W519-22 • A user-friendly web interface to various prediction methods.
122. Schuler MM, Dönnes P, Nastke MD, et al. SNEP: SNP-derived epitope prediction program for minor H antigens. Immunogenetics 2005;57:816-820 (Pubitemid 41817939)
123. Sette A, Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 2003;15:461-470 (Pubitemid 36934509)
124. Gross D-A, Graff-Dubois S, Opolon P, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004;113:425-433 (Pubitemid 38544186)
125. Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998;188:1553-1561 (Pubitemid 28516100)
126. Tangri S, Ishioka GY, Huang X, et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 2001;194:833-846 (Pubitemid 32983018)
127. Vertuani S, Sette A, Sidney J, et al. Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J Immunol 2004;172:3501-3508 (Pubitemid 38337930)
128. Stuge TB, Holmes SP, Saharan S, et al. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med 2004;1:e28 (Pubitemid 40418868)
129. Gnjatic S, Jäger E, Chen W, et al. CD8. T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci USA 2002;99:11813-11818
130. Doytchinova IA, Walshe VA, Jones NA, et al. Coupling in silico and in vitro analysis of peptide-MHC binding: a bioinformatic approach enabling prediction of superbinding peptides and anchorless epitopes. J Immunol 2004;172:7495-7502
131. Bhasin M, Raghava GPS. Prediction of promiscuous and high-affinity mutated MHC binders. Hybrid Hybridomics 2003;22:229-234 (Pubitemid 37102751)
132. Houghton CSB, Engelhorn ME, Liu C, et al. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine 2007;25:5330-5342 (Pubitemid 46977537)
133. Douat-Casassus C, Marchand-Geneste N, Diez E, et al. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells. J Med Chem 2007;50:1598-1609 (Pubitemid 46564380)
134. Groot ASD, Marcon L, Bishop EA, et al. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 2005;23:2136-2148 (Pubitemid 40341440)
135. Vider-Shalit T, Raffaeli S, Louzoun Y. Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome. Mol Immunol 2007;44:1253-1261 (Pubitemid 44415968)
136. Toussaint NC, Dönnes P, Kohlbacher O. A mathematical framework for the selection of an optimal set of peptides for epitope-based vaccines. PLoS Comput Biol 2008;4:e1000246 •• A highly flexible mathematical framework that allows the efficient identification of optimal sets of epitopes for epitope-based vaccines.
137. Toussaint NC, Kohlbacher O. OptiTope-a web server for the selection of an optimal set of peptides for epitope-based vaccines. Nucleic Acids Res 2009;37:W617-22
138. Fischer W, Perkins S, Theiler J, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007;13:100-106 (Pubitemid 46067393)
139. Nickle DC, Rolland M, Jensen MA, et al. Coping with viral diversity in HIV vaccine design. PLoS Comput Biol 2007;3:e75 (Pubitemid 46683457)
140. Kong W-P, Wu L, Wallstrom TC, et al. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 2009;83:2201-2215